A Phase 1/1b Study of ASP2138 as Monotherapy and in Combination with Pembrolizumab and mFOLFOX6 or Ramucirumab and Paclitaxel in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with mFOLFIRINOX in Participants with Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression

Protocol No
ASTELLAS-2138-CL-0101
Staff Member
Mandana Kamgar
Phase
I
Summary

This project is being done to see if a study drug called ASP2138 is safe and effective for
people diagnosed with tumors known to have Claudin [CLDN] 18.2 expression.
Objective
ASP2138 in Adults With Stomach Cancer or Pancreatic Cancer
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer, Pancreas/Liver, Other Gastrointestinal, Gastrointestinal Cancers
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT05365581